🔍 What Is Gout?

Gout is the most common crystalline inflammatory arthritis, resulting from deposition of monosodium urate (MSU) crystals in joints and soft tissues; this typically occurs when serum uric acid exceeds ~6.8 mg/dL, exceeding crystallization thresholds OHSU+15PMC+15BioMed Central+15. The first metatarsophalangeal (MTP) joint (podagra) is affected in ~50% of cases. Gout flares are driven by innate immune activation, especially via the NLRP3 inflammasome Wikipedia+1PMC+1.

🌐 Epidemiology

• Global prevalence rose by ~22.5% from 1990 to 2020, affecting ~660 per 100,000 people (~55.8 million individuals) publichealth.jmir.org+3clinexprheumatol.org+3The Lancet+3.
• Prevalence in developed nations: 3–5% adults, increasing—e.g. 3.6% to 5.1% in the US (2011–2018) .
• Incidence ~0.1–0.3% annually; male-to-female ratio roughly 3–4:1 .
• Rising incidence in adolescents has been documented, with a 23% increase from 1990 to 2021 Frontiers.
• High-risk groups include individuals in high-SDI countries, those with obesity, renal impairment, and metabolic syndrome Frontiers+2PMC+2publichealth.jmir.org+2.

🧬 Pathophysiology

• Hyperuricemia arises from impaired renal excretion (90%) or overproduction (~10%) MDPI.
• Predisposition involves genetic variants in transporters like SLC2A9, ABCG2, and SLC22A12 clinexprheumatol.org.
• MSU crystals activate the NLRP3 inflammasome, releasing IL-1β and triggering acute inflammation MDPI+1PMC+1.

⚠️ Risk Factors

• Non-modifiable: Male sex, older age (post‑menopausal in women), family history, genetic predisposition.
• Modifiable: Obesity, hypertension, dyslipidemia, CKD, metabolic syndrome, diet (red meat, seafood, fructose, alcohol), certain medications (diuretics, low-dose aspirin, cyclosporine) .
• Environmental exposures: lead toxicity, chemotherapy, systemic disease.

🩺 Clinical Presentation & Staging

• Acute gout: Rapid onset (<12 hours) of intense monoarticular joint pain—most often 1st MTP—accompanied by swelling, erythema, and warmth Wikipedia.
• Systemic symptoms: mild fever, malaise.
• Stages of gout:
  1. Asymptomatic hyperuricemia
  2. Acute intermittent gout (flair & remission)
  3. Intercritical gout (no symptoms between flares)
  4. Chronic tophaceous gout (tophi, erosive disease)

🧪 Differential Diagnosis

Consider:

• Pseudogout (CPPD)
• Septic arthritis
• Psoriatic or reactive arthritis
• Rheumatoid arthritis
• Osteoarthritis flare
• Cellulitis, bursitis, tenosynovitis

🔬 Investigations

• Synovial fluid analysis: pathognomonic MSU crystals (needle-shaped, strong negative birefringence) OHSUPMC+15Wikipedia+15PMC+15jrd.or.kr+1verywellhealth.com+1.
• Serum uric acid: may be normal during acute attacks.
• Inflammatory markers: CRP/ESR elevated.
• Renal function & lipids: evaluate comorbidities.
• Imaging:
  • US/DECT: detect tophi and crystal deposits even interictally Wikipedia.
  • X-ray: chronic erosions with overhanging edges.

🧾 Management

Acute Gout

According to 2020 ACR guidelines:

• Options: NSAIDs, colchicine, or systemic corticosteroids are all viable first-line treatments PMC+2PMC+2rheumatology.org+2.
• Low-dose colchicine: 1.2 mg then 0.6 mg an hour later. Higher doses avoided due to GI toxicity Wikipedia.
• Intra-articular steroids or joint aspiration with steroid injection useful for large joints.

Chronic Management & Prophylaxis

• Target serum urate < 6 mg/dL (< 5 mg/dL with tophi) OHSU.
• Urate-lowering therapies (ULT):
  • Allopurinol preferred first-line; start low (100 mg/d, adjust by renal function), titrate q2–5 weeks Agency for Care Effectiveness+2PMC+2thescottishsun.co.uk+2OHSU+1Wikipedia+1.
  • Febuxostat alternative if allopurinol-intolerant.
  • Uricosurics (probenecid, benzbromarone) appropriate in under-excretors.
  • Pegloticase used for refractory, tophaceous gout.
• Flare prophylaxis during ULT initiation (6+ months): low-dose colchicine, NSAIDs, or prednisone OHSUAgency for Care Effectiveness.
• Lifestyle: diet modification, weight loss, alcohol reduction, hydration, treat comorbidities, and switch diuretics to uricosuric agents (e.g., losartan) .

🏥 Complications

• Tophi: collections of MSU in soft tissues leading to deformity and erosions.
• Urolithiasis: urate stones in 10–40% of patients.
• Urate nephropathy: kidney impairment.
• Cardiovascular risk: flares associated with transient CV events; gout independently linked to HTN, diabetes, CKD, and mortality .

📊 Prognosis

• ~60% experience a recurrent flare within 1 year if untreated .
• Early and sustained urate control reverses tophi and limits joint damage.
• Life expectancy modestly reduced (~13%) due to comorbidity burden.

✅ Key Takeaways

• Gout is a common, rising, systemic inflammatory disease with crystal-driven pathophysiology.
• Diagnosis requires confirmation of MSU in fluid; imaging assists in subclinical detection.
• Management encompasses acute control and chronic urate lowering, guided by 2020 ACR/NICE recommendations OHSU.
• Addressing comorbidities and risk factors is essential to optimize outcomes.